去唾液酸糖蛋白受体和脂质素协同介导原代大鼠肝细胞基因转移

以阳离子脂质素作为DNA运载体 ,以肝细胞去唾液酸糖蛋白受体 (ASGPR)的天然配体去唾液酸胎球蛋白 (ASF)作为导向配体 ,用于介导原代大鼠肝细胞基因转移 .结果表明转染复合物中加入ASF可明显提高肝细胞转染率 ,并且明显降低高比例脂质素 DNA复合物转染细胞时对细胞的毒性作用 ,ASGPR的化学合成配体半乳糖基白蛋白在基因转移中亦与ASF具有同样的作用 .因此ASGPR可与阳离子脂质素协同介导肝细胞基因转移 ,为原代肝细胞基因转移提供了一种更为简便、实用、有效的方法 ,有应用于肝基因治疗的前景 .     

肝靶向配体半乳糖基白蛋白和多聚谷氨酸

化学合成两类去唾液酸糖蛋白受体(ASGPR)的人工配体——半乳糖基白蛋白(Gal_nHSA)和半乳糖基多聚-L-谷氨酸(Gal_nPLGA), 并以 ¹²⁵I标记的去唾液酸胎球蛋白(ASF)为标准配体,测定了合成配体抑制 ¹²⁵I-ASF与大鼠肝细胞膜ASGPR结合的IC₅₀值. 结果表明,Gal₁₂HSA、Gal₁₅HSA、Gal₂₆HSA、Gal₃₀HSA和Gal₃₄PLGA均能够有效地抑制 ¹²⁵I-ASF与ASGPR的结合,且前者与ASGPR的亲和力随半乳糖基化程度的增加而增加. 这些合成配体来源丰富、制备简单,适合于作为药物或基因肝靶向运送的导向配体.     

肝细胞表面去唾液酸糖蛋白受体的流式细胞分析

建立肝细胞表面去唾液酸糖蛋白受体（ASGPR）的流式细胞分析方法（FCM）,对正常及损伤鼠肝细胞、肝癌细胞（BEL-7402）表面的ASGPR作同步比较分析.以异硫氰酸荧光素标记的新半乳糖白蛋白（FITC-NGA）为ASGPR的特异性配体,以培养的正常肝细胞（L-02）为靶细胞,建立肝细胞表面ASGPR的FCM.测定并计算正常及损伤鼠肝细胞,BEL-7402细胞与同一浓度的FITC-NGA同步反应后的平均荧光强度（MIF）值.FITC-NGA与L-02细胞表面ASGPR趋近饱和结合的浓度为0.4 mg/L,该浓度下正常及损伤鼠肝细胞,BEL-7402细胞的MIF值分别为228.7、5.81、1.13.该结合可以被至少50倍于FITC-NGA的NGA或10 mmol/L的EDTA完全抑制.FCM能够良好地揭示FITC-NGA同ASGPR之间的受配体结合特性.该方法证实BEL-7402细胞表面几乎没有ASGPR,损伤鼠肝细胞表面ASGPR的数量较正常鼠肝细胞显著减少.     

肝脏去唾液酸糖蛋白受体及其应用

去唾液酸糖蛋白受体 (ａｓｉａｌｏｇｌｙｃｏｐｒｏｔｅｉｎｒｅｃｅｐｔｏｒ,简称ＡＳＧＲ)是数量丰富的一种异源低聚物的内吞受体 ,主要存在于肝脏实质细胞朝向窦状隙一侧的细胞膜表面[1] ,具有对糖的特异性 ,并有特定的生物学功能 ,所以又称为肝糖凝集蛋白或肝凝集素。由于各种糖蛋白在用酶水解或用酸解除去末端唾液酸后 ,暴露出的次末端是半乳糖残基 ,所以ＡＳ ＧＲ的糖结合特异性实际上在于半乳糖基 ,故又称半乳糖特异性受体。ＡＳＧＲ的主要功能是去除去唾液酸糖蛋白和调亡细胞、清除脂蛋白 ,同时又是肝病毒的侵入位点[2 ] 。ＡＳ Ｇ…     

昆虫细胞内N-糖基化途径及人源化糖蛋白表达

虽然昆虫杆状病毒表达系统在蛋白表达领域得到了广泛的应用, 但由于不能表达复杂的末端唾液酸化的N-糖链, 使得该系统在生物制药行业的应用受到了很大的限制。通过比较哺乳动物细胞和昆虫细胞内糖基化途径可知, 其起始步骤一致, 之后再发生分化, 主要表现为3方面, 即昆虫细胞内缺乏哺乳动物细胞所具备的N-乙酰葡萄糖氨转移酶II、 半乳糖基转移酶/N-乙酰氨基半乳糖转移酶、α-2,3-唾液酸转移酶和α-2,6-唾液酸转移酶等延长N-糖链的糖基转移酶; 另外, 昆虫细胞内具有能够特异性地将蛋白质末端的N-乙酰氨基葡萄糖残基从GlcNAcMan3GlcNAc(±α3/6-Fuc)GlcNAc上切除的N-乙酰氨基葡萄糖苷酶及核心α-1,3-岩藻糖基转移酶。本文从上述异同出发, 综述了克服昆虫细胞内不能表达人源化糖蛋白这一缺陷所进行的N-糖基化途径的改造研究--主要集中在昆虫细胞内GlcNAcase的抑制和昆虫细胞内GnT2, GalT/ GalNAcT, ST3及ST6等基因的导入等方面, 结果表明经改造的昆虫细胞可表达人源化糖蛋白, 这将极大地拓宽昆虫杆状病毒表达系统的应用领域。本文还探讨了选择特殊细胞系及特殊培养条件以在昆虫细胞内表达唾液酸化蛋白的可行性。     

肝脏去唾液酸糖蛋白受体特异性RNA适配子的SELEX筛选与鉴定

目的获得能够特异性高亲和力结合肝脏特异性去唾液酸糖蛋白受体（asialoglycoprotein receptor,ASGPR）的RNA适配子,为开发诊断和治疗肝脏疾病的靶向性试剂和药物奠定基础。方法合成一个长度为115nt含有25个随机序列的单链DNA随机文库,通过体外转录构建出单链RNA适配子随机文库,以肝脏ASGPR大亚基为靶蛋白,采用SELEX（systematic evolution of ligands by exponential enrichment）技术筛选具有高亲和力的AsGPR特异性RNA适配子;通过膜结合测定实验、凝胶阻滞实验鉴定筛选适配子对靶蛋白的特异性和亲和力。结果经过12轮筛选获得了具有高亲和力的肝脏ASGPR特异性RNA适配子。结论成功地筛选出了具有离亲和力的肝脏ASGPR特异性RNA适配子库。     

表达乙肝病毒受体人ASGPR转基因小鼠的建立

目的：建立表达乙肝病毒受体人ASGPR的转基因小鼠。方法：克隆人的脱唾液酸糖蛋白受体（ASGPR）两个亚基的cDNA,连入PCAGGS构建转基因表达载体,以显微共注射的方法将两种各3.9kb的转基因片段引入小鼠的受精卵。采用PCR、Southern印迹、RT-PCR、Western印迹的方法对转基因小鼠进行鉴定。结果与结论：获得了在小鼠肝脏组织中共表达有乙肝病毒（HBV）受体ASGPR H1和ASGPR H2的一个转基因小鼠系,可为HBV的研究提供一种良好的感染动物模型。     

表达人去唾液酸糖蛋白受体分子细胞系的建立

目的构建稳定表达人肝细胞表面分子去唾液酸糖蛋白受体（asialoglycoprotein receptor,ASGPR）的细胞系。方法逆转录PCR扩增人肝组织ASGPR大亚基H1全编码序列,插入到真核表达载体plRES2EGFP中,重组质粒pIRES2EGFP／ASGPRH1转染HeLa细胞,G418筛选,RT—PCR,Western印迹及免疫荧光检测ASGPRH1的表达。结果成功构建了pIRES2EGFP／ASGPRH1重组质粒,该质粒转染HeLa细胞后,Western印迹及免疫荧光均检测到ASGPRHI蛋白的表达。结论成功建立了稳定表达人ASGPRH1的细胞系,为进一步研究ASGPR分子奠定了基础。     

H7N2禽流感病毒HA的分离纯化及其糖链谱研究

血凝素(HA)是位于流感病毒囊膜表面的一种Ⅰ型跨膜糖蛋白,是流感病毒结合宿主细胞表面受体,介导病毒入胞的关键分子,也是中和抗体以及疫苗研制的重要靶标.HA表面糖基化与病毒毒力、感染宿主范围等密切相关,且其表面糖链变化会影响其结构与功能.然而目前关于流感病毒HA糖基化的研究主要集中在其糖基化位点上,而对于HA上详细的糖链结构知之甚少.本文应用禽流感病毒特异识别的唾液酸糖链(SAα2-3Gal)受体,制备特异的糖链磁性微粒复合物,进而从H7N2禽流感病毒中分离纯化HA,并采用SDS-PAGE及质谱技术进行鉴定.确定提取物系HA后,进一步利用凝集素芯片联合质谱技术研究禽流感病毒H7N2的HA表面糖型,结果显示H7N2禽流感病毒HA表面主要含有岩藻糖、半乳糖、N-乙酰半乳糖胺、甘露糖、N-乙酰葡糖胺等糖链结构,共获得16个糖链结构较为准确的寡糖,这些糖链可能与HA生物学功能相关.本研究有助于揭示禽流感病毒感染宿主的糖链作用机制,有助于设计制备针对HA相关的糖链疫苗.     

鲫鱼籽唾液酸糖蛋白的N-糖链结构及生物活性

鲫鱼是常规食用淡水鱼,其鱼籽含有大量唾液酸化糖蛋白。对鲫鱼籽糖蛋白进行纯化,研究其N-糖链结构和生物活性。结果发现:鲫鱼籽糖蛋白分子量主要分布在19.7×10~4、2.7×10~4和2.2×10~4左右。利用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)解析主要糖蛋白上N-糖链,发现其N-糖链结构主要为双天线型或三天线型分叉结构,末端唾液酸结合在半乳糖或N-乙酰氨基-半乳糖上。生物活性分析表明,鲫鱼籽糖蛋白具有阻止磷酸钙沉淀能力和一定清除DPPH自由基能力,对HaCat细胞具有促生长能力,并具有较强的促凝血活性。     

Asialoglycoprotein receptor and liposome synergistically mediate the gene transfer into primary rat hepatocytes

Gene transfer into primary rat hepatocytes was performed by employing cationic liposome as DNA carrier and the specific ligand of hepatic asialoglycoprotein receptor (ASGPR), asialofetuin, as liver-targeting ligand. The resuits showed that asialofetuin, when added to the gene transfer complexes, could significantly increase the hepatocyte transfeetion efficiency, and alleviate the cellular toxicity of Lipofectin. Several synthetic ligands of ASGPR (galactosyl albumin) could also increase the transfection efficiency of hepatocyte like asialofetuin. It was proved that ASGPR and cationic liposome could synergistically mediate the gene transfer into primary rat hepatoeytes. This novel gene delivery system provided a safer, more simple and efficient gene transfer method for primary hepatocytes, and showed prospecting application in hepatic gene therapy.     

Asialoglycoprotein receptor and liposome synergistically mediate the gene transfer into primary rat hepatocytes

Gene transfer into primary rat hepatocytes was performed by employing cationic liposome as DNA carrier and the specific ligand of hepatic asialoglycopmtein receptor (ASGPR), asialofetuin, as liver-targeting ligand. The results showed that asialofetuin, when added to the gene transfer complexes, could significantly increase the hepatocyte transfection efficiency, and alleviate the cellular toxicity of Lipofectin. Several synthetic ligands of ASGPR (galactosyl albumin) could also increase the transfection efficiency of hepatocyte like asialofetuin. It was proved that ASGPR and cationic liposome could synergistically mediate the gene transfer into primary rat hepatocytes. This novel gene delivery system provided a safer, more simple and efficient gene transfer method for primary hepatocytes, and showed prospecting application in hepatic gene therapy.     

Ligand- and weak base-induced redistribution of asialoglycoprotein receptors in hepatoma cells

The receptor for asialoglycoproteins (ASGPR) was localized in human hepatoma Hep G2 cells by means of quantitative immunoelectron microscopy. Without ligand added to the culture medium, we found 34% of the total cellular receptors on the plasma membrane, 37% in compartment of uncoupling receptor and ligand (CURL), and 21% in a trans-Golgi reticulum (TGR) that was defined by the presence of albumin after immuno-double labeling. A small percent of the ASGPR was associated with coated pits, the Golgi stacks, and lysosomes. After incubation of the cells with saturating concentrations of the ligand asialo-orosomucoid (ASOR), the number of cell surface receptors decreased to 20% of total cellular receptors, whereas the receptor content of CURL increased by a corresponding amount to 50%. The ASGPR content of TGR remained constant. In contrast, after treatment of the cells with 300 microM of the weak base primaquine (PMQ), cell surface ASGPR had decreased dramatically to only 4% of total cellular receptors whereas label in the TGR had increased to 42%. ASGPR labeling of CURL increased only to 47%. The labeling of other organelles remained unchanged. This affect of PMQ was independent of the presence of additional ASOR. Implications for the intracellular pathway of the ASGPR are discussed.     

Composition,Antigenic Properties and Hepatocyte Surface Expression of the Woodchuck Asialoglycoprotein Receptor

Abstract

We have purified woodchuck hepatic asialoglycoprotein receptor (ASGPR) by ligand affinity chromatography and have identified it as a heterooligomeric complex comprised of two subunits with molecular masses of 40 and 47 kD, designated as woodchuck hepatic lectin 1 and 2 (WHL1 and WHL2), respectively. With the help of antisera generated against the soluble, bioactive woodchuck and rabbit ASGPRs and anti-subunit monospecific antibodies, distinct antigenic specificity of each of the ASGPR polypeptide subunits and interspecies immunologic cross-reactivity of the receptor polypeptides displaying comparable molecular masses were documented. In contrast to the purified woodchuck receptor, WHL2 antigenic reactivity was not identifiable in woodchuck hepatocyte plasma membranes unless the intact membranes were exposed to an asialylated ligand or a soluble membrane fraction was incubated with anti-receptor antibody. These findings imply that both WHL1 and WHL2 are expressed on the hepatocyte surface and contribute to ligand binding, since antibody specific to either subunit blocks ligand attachment. Our results also indicate that ligand binding modifies antigenic properties of the membrane expressed ASGPR.     

Hepatocyte-targeting gene delivery using a lipoplex composed of galactose-modified aromatic lipid synthesized with click chemistry

Highly efficient drug carriers targeting hepatocyte is needed for treatment for liver diseases such as liver cirrhosis and virus infections. Galactose or N-acetylgalactosamine is known to be recognized and incorporated into the cells through asialoglycoprotein receptor (ASGPR) that is exclusively expressed on hepatocyte and hepatoma. In this study, we synthesized a galactose-modified lipid with aromatic ring with click chemistry. To make a complex with DNA, termed ‘lipoplex’, we prepared a binary micelle composed of cationic lipid; dioleoyltrimethylammoniumpropane (DOTAP) and galactose-modified lipid (D/Gal). We prepared lipoplex from plasmid DNA (pDNA) and D/Gal and examined the cell specificity and transfection efficiency. The lipoplex was able to interact with ASGPR immobilized on gold substrate in the quartz-crystal microbalance (QCM) sensor cell. The lipoplex induced high gene expression to HepG2 cells, a human hepatocellular carcinoma cell line, but not to A549 cells, a human alveolar adenocarcinoma cell line. The treatment with asialofetuin, which is a ligand for ASGPR and would work as a competitive inhibitor, before addition of the lipoplexes decreased the expression to HepG2 cells. These results indicate that D/Gal lipoplex was incorporated into HepG2 cells preferentially through ASGPR and the uptake was caused by galactose specific receptor. This delivery system to hepatocytes may overcome the problems for gene therapy and be used for treatment of hepatitis and hepatic cirrhosis.     

A pool of intracellular phosphorylated asialoglycoprotein receptors which is not involved in endocytosis

One proposed function of the asialoglycoprotein receptor in hepatocytes is to mediate the endocytosis of galactose and N-acetylgalactosamine-exposing glycoproteins. Recently we defined a pool of intracellular H1 subunits of the asialoglycoprotein receptor (ASGPR) in the human hepatoma cell line HepG2 which appeared not to be involved in endocytosis (Stoorvogel, W., Geuze, H. J., Griffith, J. M., Schwartz, A. L., and Strous, G. J. (1989) J. Cell Biol. 108, 2137-2148). In addition, a pool of stably phosphorylated intracellular ASGPR has been detected (Fallon, R. J., and Schwartz, A. L. (1988) J. Biol. Chem. 263, 13159-13166). In the current study we integrate these findings and provide evidence for the existence of two types of intracellular nonexchangeable compartments containing ASGPR. A transiently phosphorylated pool of ASGPR shuttles between the plasma membrane and endosomes, via a pathway identical to that of the transferrin receptor. The second pool comprises 20% of the total intracellular ASGPR, is stably phosphorylated at a serine residue, and is located in intracellular compartments devoid of recycling transferrin receptor. We refer to this ASGPR pool as the "silent pool." We furthermore show that the two receptor pools are confined to compartments exhibiting different buoyant densities on sucrose density gradients. ASGPR in the "silent pool" is fully glycosylated, suggesting a post-Golgi sorting mechanism for trafficking to this compartment. Possible functions of the "silent" ASGPR pool are discussed.     

Capacity limits of asialoglycoprotein receptor-mediated liver targeting

The abundant cell surface asialoglycoprotein receptor (ASGPR) is a highly selective receptor found on hepatocytes that potentially can be exploited as a selective shuttle for delivery. Various nucleic acid therapeutics that bind ASGPR are already in clinical development, but this receptor-mediated delivery mechanism can be saturated, which will likely result in reduced selectivity for the liver and therefore increase the likelihood for systemic adverse effects. Therefore, when aiming to utilize this mechanism, it is important to optimize both the administration protocol and the molecular properties. We here present a study using a novel ASGPR-targeted antibody to estimate ASGPR expression, turnover and internalization rates in vivo in mice. Using pharmacokinetic data (intravenous and subcutaneous dosing) and an in-silico target-mediated drug disposition (TMDD) model, we estimate an ASGPR expression level of 1.8 million molecules per hepatocyte. The half-life of the degradation of the receptor was found to be equal to 15 hours and the formed ligand-receptor complex is internalized with a half-life of 5 days. A biodistribution study was performed and confirmed the accuracy of the TMDD model predictions. The kinetics of the ASGPR shows that saturation of the shuttle at therapeutic concentrations is possible; however, simulation allows the dosing schedule to be optimized. The developed TMDD model can be used to support the development of therapies that use the ASGPR as a shuttle into hepatocytes.